Abbott reports positive trial data for FreeStyle Libre system

Abbott has announced the results of a new clinical study showing the benefits its FreeStyle Libre system can provide for people with type 1 diabetes.

Results from the IMPACT clinical trial demonstrated that FreeStyle Libre met its primary endpoint of a reduction in time spent in hypoglycaemia among those enrolled in the study.

Users of the sensor and reader system were shown to have spent 38 percent less time in a hypoglycaemic state compared to those managing their glucose with traditional self-monitoring of blood glucose systems.

FreeStyle Libre system also helped to reduce all measures of hypoglycaemia without increasing glucose levels in the blood, showing that the FreeStyle Libre system can safely and successfully replace the need for routine finger pricks as a means of managing diabetes. 

Jared Watkin, senior vice-president for diabetes care at Abbott, said: "Our goal is to help our customers be healthier and live fuller lives, and it's clear from this trial that FreeStyle Libre provides our customers just what they need to do that."

FreeStyle Libre system is factory calibrated and does not require a finger stick test for calibration, where other continuous glucose monitoring systems might require two or more per day.